Fig. 2From: FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinomaValidation of the cutoff point used in the preliminary report. We validated the usefulness of max SUVmax 8.8 [12], focusing on the 77 patients who were enrolled after the preliminary analysisBack to article page